Medical device company AtriCure upgraded to "Outperform" by Oppenheimer, target price $32.
Medical device company AtriCure has been upgraded to an "Outperform" rating by Oppenheimer, with a target price of $32. The firm recently reported Q1 earnings, posting ($0.21) EPS, beating consensus estimates of ($0.22) by $0.01. The majority of analysts have a "buy" rating for the company, giving AtriCure a consensus rating of "Moderate Buy" and a consensus price target of $52.63.
April 26, 2024
3 Articles